Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Get Free Report) saw unusually-high trading volume on Monday . Approximately 342,761 shares were traded during mid-day trading, a decline of 43% from the previous session's volume of 599,397 shares.The stock last traded at $33.25 and had previously closed at $32.19.
Analyst Upgrades and Downgrades
AGIO has been the topic of several recent research reports. Cantor Fitzgerald restated an "overweight" rating on shares of Agios Pharmaceuticals in a research note on Wednesday, December 18th. Leerink Partnrs downgraded Agios Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a report on Friday, September 27th. StockNews.com upgraded Agios Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Saturday, November 9th. Royal Bank of Canada boosted their price target on shares of Agios Pharmaceuticals from $55.00 to $57.00 and gave the company an "outperform" rating in a research report on Tuesday, December 10th. Finally, Scotiabank boosted their price objective on shares of Agios Pharmaceuticals from $53.00 to $75.00 and gave the company a "sector outperform" rating in a research report on Monday, December 9th. Five research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat.com, Agios Pharmaceuticals presently has an average rating of "Hold" and a consensus target price of $56.33.
Get Our Latest Analysis on AGIO
Agios Pharmaceuticals Stock Performance
The stock has a market capitalization of $1.91 billion, a PE ratio of 2.95 and a beta of 0.87. The stock has a 50-day moving average price of $47.38 and a two-hundred day moving average price of $45.70.
Hedge Funds Weigh In On Agios Pharmaceuticals
A number of institutional investors have recently made changes to their positions in AGIO. Erste Asset Management GmbH acquired a new position in Agios Pharmaceuticals during the 3rd quarter worth $97,199,000. Marshall Wace LLP lifted its holdings in shares of Agios Pharmaceuticals by 307.8% during the 2nd quarter. Marshall Wace LLP now owns 1,133,735 shares of the biopharmaceutical company's stock worth $48,887,000 after acquiring an additional 855,739 shares during the period. Vestal Point Capital LP purchased a new stake in shares of Agios Pharmaceuticals in the third quarter valued at about $33,767,000. Frazier Life Sciences Management L.P. boosted its stake in Agios Pharmaceuticals by 66.7% in the second quarter. Frazier Life Sciences Management L.P. now owns 871,974 shares of the biopharmaceutical company's stock valued at $37,600,000 after acquiring an additional 348,808 shares during the last quarter. Finally, Candriam S.C.A. bought a new stake in Agios Pharmaceuticals in the second quarter valued at $13,922,000.
About Agios Pharmaceuticals
(
Get Free Report)
Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.
Further Reading
Before you consider Agios Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Agios Pharmaceuticals wasn't on the list.
While Agios Pharmaceuticals currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
